Molecular epidemiology of extended-spectrum beta-lactamase-producing *Escherichia coli* in Tunisia and characterization of their virulence factors and plasmid addiction systems

Basma Mnif1,3,4*, Hela Harhour1,4, Jihène Jdidi2, Faouzia Mahjoubi1,4, Nathalie Genel3, Guillaume Arlet3 and Adnene Hammami1,4

**Abstract**

**Background:** Extended-spectrum β-lactamases (ESBLs), particularly CTX-M- type ESBLs, are among the most important resistance determinants spreading worldwide in Enterobacteriaceae [1,2]. During the 1980s, ESBLs evolved from TEM and SHV broad-spectrum-β-lactamases, frequently associated to *Klebsiella pneumoniae* involved in nosocomial outbreaks. Over the last decade, CTX-M-type ESBLs have increased dramatically, and become the most prevalent ESBLs worldwide, frequently associated to *Escherichia coli*. Among the CTX-M-type ESBLs, CTX-M-15 is now the most widely distributed in *E. coli* which became a major cause of infections in both community and hospitals [1,2]. A few explanations have been proposed on what makes CTX-M-15-producing *E. coli* isolates so successful. First, it has been proposed that the strain virulence background could be involved in this dissemination process. In fact, many reports have shown that CTX-M-15 is closely associated with the international and pandemic uropathogenic O25:H4-ST131 clone, which have specific virulence factors [3,4]. Second, the association of CTX-M-15 with the IncF plasmids, which are well adapted to *E. coli*, may facilitate the spread

**Results:** The collection comprised 163 ESBL producers collected from two university hospitals of Sfax between 1989 and 2009. 118 isolates harbored *bla*<sub>CTX-M</sub> gene (101 *bla*<sub>CTX-M-15</sub> gene and 17 *bla*<sub>CTX-M-14</sub> gene). 49 isolates carried *bla*<sub>SHV-12</sub> gene, 9 *bla*<sub>SHV-2a</sub> gene and only 3 *bla*<sub>TEM-26</sub> gene. 16 isolates produced both CTX-M and SHV-12. The 101 CTX-M-15-producing isolates were significantly associated to phylogroup B2 and exhibiting a high number of virulence factors. 24 (23.7%) of the group B2 isolates belonged to clonal complex ST131. Pulsed-field gel electrophoresis (PFGE) typing revealed a genetic diversity of the isolates. 144 ESBL determinants were transferable mostly by conjugation. The majority of plasmid carrying *bla*CTX-M-15 genes (72/88) were assigned to various single replicon or multireplicon IncF types and had significantly a higher frequency of addiction systems, notably the VagCD module.

**Conclusion:** This study demonstrates that the dissemination of CTX-M-15 producing *E. coli* in our setting was due to the spread of various IncF-type plasmids harboring multiple addiction systems, into related clones with high frequency of virulence determinants.

**Keywords:** *E. coli*, ESBL, CTX-M-15, Plasmid, Addiction systems, Virulence

---

**Background**

Extended-spectrum β-lactamases (ESBLs) are among the most important resistance determinants spreading worldwide in Enterobacteriaceae [1,2]. During the 1980s, ESBLs evolved from TEM and SHV broad-spectrum-β-lactamases, frequently associated to *Klebsiella pneumoniae* involved in nosocomial outbreaks. Over the last decade, CTX-M-type ESBLs have increased dramatically, and become the most prevalent ESBLs worldwide, frequently associated to *Escherichia coli*. Among the CTX-M-type ESBLs, CTX-M-15 is now the most widely distributed in *E. coli* which became a major cause of infections in both community and hospitals [1,2]. A few explanations have been proposed on what makes CTX-M-15-producing *E. coli* isolates so successful. First, it has been proposed that the strain virulence background could be involved in this dissemination process. In fact, many reports have shown that CTX-M-15 is closely associated with the international and pandemic uropathogenic O25:H4-ST131 clone, which have specific virulence factors [3,4]. Second, the association of CTX-M-15 with the IncF plasmids, which are well adapted to *E. coli*, may facilitate the spread...
of this determinant in *E. coli* population [5]. In addition to virulence background and IncF plasmids bearing CTX-M-15, it was recently suggested that the association of various plasmid addiction systems may contribute to the plasmid maintenance in their host [6-8]. An addiction system or a toxin-antitoxin system helps maintain plasmids in bacteria during host replication by killing of plasmid-free cells resulting from segregation or replication defects [9].

In Tunisia, SHV-2 was the first ESBL to be detected, in 1984 from a *K. pneumoniae* clinical isolate [10]. Then, various other types of ESBLs, SHV-12, SHV-2a, CTX-M-15, CTX-M-14, CTX-M-9, CTX-M-16, CTX-M-27 and CTX-M-28 have been reported in different Tunisian hospitals with CTX-M-15 being the most prevalent [11-15]. This study was designed to characterize the ESBL-producing *E. coli* collected in two university hospitals of Sfax, in the southern part of Tunisia and to investigate their virulence background, their ESBL-encoding plasmids and their plasmid addiction systems.

### Methods

**E. coli isolates**

163 isolates were randomly selected from the collection of ESBL-producing *E. coli* isolates maintained at -80°C in the Microbiology laboratory of Habib Bourguiba hospital. The 163 isolates were collected from the two university hospital of Sfax in Tunisia during the following years: 1989-1990 (6), 2000 (9), 2001 (18), 2002 (9), 2003 (30), 2004 (26), 2006 (36) and 2009 (29). These isolates were obtained mainly from urine (124), but also from blood (20), wound swabs (10), abdominal fluid (5) and sputum (4).

**Antibiotic susceptibility testing**

The susceptibility to 16 antimicrobial agents (amoxicillin, amoxicillin + clavulanic acid, ticarcillin, ticarcillin + clavulanic acid, cefalothin, cefoxitin, ceftazidime, cefotaxime, amoxicillin + clavulanic acid, ticarcillin, ticarcillin + clavulanic acid, cefalothin, cefoxitin, ceftazidime, cefotaxime, cefepime, gentamicin, amikacin, nalidixic acid, norfloxacin, sulfamethoxazole/trimethoprim and tetracycline) was determined by the disk diffusion method according to the guidelines of the CLSI [16]. All isolates were confirmed for ESBL production using the double disk synergy method.

**Identification of bla genes**

The resistance genes *bla*TEM, *bla*SHV and *bla*CTX-M responsible for the ESBL activity were identified by PCR-sequencing [17]. PCR products were sequenced on ABI Prism 3100 automated sequencer (Applied Biosystems, Foster City, CA) and were analyzed using NCBI BLAST program. (http://www.ncbi.nlm.nih.gov/).

### Strain typing

The phylogenetic group of the ESBL-producing *E. coli* was determined by a multiplex PCR assay [18]. Isolates belonging to phylogenetic group B2 were screened with a previously established PCR-based method to identify the O25b subtype [19]. Furthermore, multilocus sequence typing (MLST) using the scheme of the Institut Pasteur, Paris, France (www.pasteur.fr/mlst) was used to confirm that CTX-M-15-producing *E. coli* O25b belonged to the international clone ST131 [19]. Genetic relatedness of the ESBL-producing strains was studied by PFGE following extraction of genomic DNA and digestion with *XbaI* PFGE according to a standard protocol using a GenePath system (Bio-Rad). PFGE banding profiles were compared digitally using Fingerprint II software (Bio-Rad) and relatedness was calculated using the unweighted pair group method with arithmetic mean (UPGMA) algorithm with similarity of bands using the Dice similarity indices. Isolates were considered to belong to the same PFGE cluster if their Dice similarity index was >80% [20].

### Transfer of ESBL resistance determinants and plasmid analysis

Transfer of ESBL encoding genes by conjugation was performed by matting-out assays using *E. coli* J53-2 RifR or *E. coli* HB101 StrR as recipient strains. Transconjugants were selected on MH agar containing rifampin (250 μg/mL) or streptomycin (50 μg/mL) plus ceftazidime or cefotaxime (2 μg/mL). When plasmids were not transferable by conjugation, a transformation experiment was assayed. Plasmid DNA obtained using the QIAprep Spin Miniprep kit (Qiagen) were electroporated into *E. coli* DH10B (Invitrogen). Transformants were selected on MH agar plates supplemented with ceftazidime (2 μg/mL) or cefotaxime (2 μg/mL). Plasmids were classified according to their incompatibility group using the PCR replicon-typing scheme described previously [21].

### Detection of virulence factors and plasmid addiction systems

For the ESBL-producing isolates, 17 virulence-associated genes were sought as previously described: *fimH* (type 1 fimbriae), *papG* (P fimbriae adhesion) alleles I, II and III, *papC*, *sfa/focDE* (S and F1C fimbriae), *afa/draBC* (Dr-binding adhesions), *iha* (adhesion siderophore), *hra* (heat-resistant agglutinin), *iutA* (aerobactin receptor), *fyuA* (yersiniaibacit receptor), *cnf-1* (cytotoxic necrotizing factor type 1), *lyA* (α-hemolysin), *sat* (secreted autoreceptor toxin), *kpsMT* II (group II capsule), *traT* (serum resistance-associated) and *pheR* (phenylalanine tRNA, site of insertion from PAI V) [22].

For *E. coli* recipient strains, seven plasmid addiction system PemK–PemI (plasmid emergency maintenance), CcdA–CcdB (coupled cell division locus) RelB–RelE
(relaxed control of stable RNA synthesis), ParD–ParE (DNA replication), VagC–VagD (virulence-associated protein), Hok–Sok (host-killing) and PndA–PndC (promotion of nucleic acid) were sought by PCR as described previously [7].

Statistical analysis
Comparisons were determined using Pearson’s x² or Fisher’s exact test when appropriate, and a P value < 0.05 was considered significant. Statistical analysis was carried out using SPSS version 11.5 for Windows.

Results
ESBL characterization and antimicrobial resistance
PCR and sequence analysis revealed that 118 of the 163 (72%) ESBL-positive E. coli clinical isolates were CTX-M producers, 101 producing CTX-M-15 and 17 CTX-M-14. 49 isolates produced SHV-12, 9 SHV-2a and only 3, TEM-26. 16 isolates were found to carry both bla SHV-12 gene and bla CTX-M gene (10 bla CTX-M-15 and 6 bla CTX-M-14 genes). The occurrence of bla SHV genes decreased over time, whereas bla CTX-M genes became predominant since 2003 (Figure 1). The ESBL-producing E. coli isolates were highly resistant to the aminoglycosides, gentamicin (78%), amikacin (32%), to fluoroquinolones (ciprofloxacin, 62%) and to trimethoprim-sulfamethoxazole (65%).

Transfer of resistance and plasmid replicon type determination
144 over 179 (80%) ESBL determinants were transferable by conjugation (n = 136) or transformation (n = 8); these encoded CTX-M-15 (n = 88), CTX-M-14 (n = 15), SHV-12 (n = 30), SHV-2a (n = 9) and TEM-26 (n = 2) (Table 1). Only the bla CTX-M gene was detected in recipient strains corresponding to E. coli isolates harboring both bla SHV-12 gene and bla CTX-M gene, except for one isolate in which the bla SHV-12 determinant was transferred. 35 ESBL determinants, were non transferable despite repeated conjugation and transformation attempts.

Fifteen of the 144 ESBL-carrying plasmids (10.4%) were non-typeable for the incompatibility groups sought by the PCR-based replicon typing; 9 of these encoded the CTX-M-14 ESBL, 4 encoded SHV-12 and 2 encoded CTX-M-15. Eighty-five of the 144 ESBL-carrying plasmids (59%) belonged to IncF replicon types. IncF replicons were associated with both SHV and CTX-M ESBL types but were significantly more prevalent in CTX-M-carrying plasmids (CTX-M ESBL type versus SHV, p < 0.001), especially CTX-M-15 ones (Table 1). In fact, 82% of CTX-M-15 genes (72/88) were carried on single FII rep type and, 24 on multiple IncFII replicons, occurring in 4 different combinations of IncFII, IncFIA, and/or IncFIB replicons, but FII-FIA-FIB (n = 15) being most frequent (Table 1). HII and A/C replicons were associated with SHV ESBL types and L/M and I1 replicons with CTX-M ESBL types (Table 1).

Strain typing
The 163 ESBL-producing E. coli isolates divided among all four major phylogenetic groups: B2 (n = 61), A (n = 54), D (n = 24) and B1 (n = 24). Group B2 was significantly more common among CTX-M-15 producers and group A among SHV producers (Table 2). RbO25 PCR and MLST revealed that 39% of the group B2 isolates (24/61) and 46.1% of the CTX-M-15-producing B2 isolates (24/52) belonged to the internationally disseminated uropathogenic clone O25:H4-ST131. Of note, these ST131 isolates were recovered mainly in 2003 and 2004 (21 ST131 isolates which accounted for 75% of the B2 isolates) and more rarely in 2006 (2 ST131 isolates) and 2009 (1 ST131 isolate). All of the 163 E. coli isolates were subjected to PFGE analysis. However, 15 isolates could not be typed by PFGE. Examination of the 148 PFGE patterns revealed a great genomic diversity with 93 different pulsotypes (62.8%) (Data not shown). 68 isolates corresponded to non-genetic-related isolates, whereas 90 isolates were assigned to 25 minor clonal groups with >80% of similarity; two clusters of 8 isolates, 4 clusters of 4 or 5 isolates and the 19 remaining clusters comprised three or two isolates. The closely related E. coli strains were isolated from different wards and years indicating both cross transmission and persistence of some clones in our settings. The SHV-producing isolates were often clonally related, whilst the CTX-M producers were more genetically diverse. Of note, the 22 ST131 strains constituted one large cluster defined at the 61% similarity level; which was closely tied to a representative strain of the ST131 clonal complex (TN03, [21]). The ST131 cluster, in turn, comprised 6 separate PFGE groups, as defined at the 80% similarity level (Figure 2).

Virulence genotyping
The results of the distribution of virulence determinants in E. coli isolates in relation with ESBL type and phylogenetic
group are reported in Table 3. All the 17 virulence factor genes sought were identified in at least 3 isolates. The most prevalent virulence genes were fimH (84.7%), followed by traT (73%), fyuA (63.8%), phaR (60.1%), and iutA (50.3%). Isolates belonging to the virulent phylogenetic groups B2 and D had averages of 8.6 and 5.2 virulence factor genes each, respectively, compared with 3 and 3.9, respectively, for isolates belonging to groups A and B1. ESBL-producing E. coli isolates belonging to group B2 were significantly more positive for the adhesins iha, sfa/foc and papG II and the toxins sat, hylA and cnf1 (p < 0.001). Accordingly, distribution rates of most virulence determinants were higher in CTX-M producing E. coli isolates than in non-CTX-M producers, as the CTX-M producers especially CTX-M-15 ones were significantly associated to phylogenetic group B2. However, the differences were not significant, except for papG allele II, iha, iutA, sat, hylA, traT, and kpsM II (Table 3). In fact the B2 isolates with CTX-M-15 had the highest mean score of 8.9 virulence factor genes (Table 3). Of note, the ST131 isolates didn’t exhibit the same virulence profiles. Only five different virulence genes were uniformly present in all 24 ST131 isolates, including fimH, iha, sat, fyuA, iutA genes and only 16 ST131 isolates belonged to 3 unique virulence profiles. The virulence profiles corresponded inconsistently with PFGE type, suggesting ongoing evolution of virulence genotypes. Moreover, these ST131 isolates were carrying 16 CTX-M-15-plasmids of different types including 7 FIA-FIB-FII, 3 FIA-FII, 3 FII, 2 I1 and one untypeable replicon.

Addiction systems of ESBL-carrying plasmids
In total, 187 plasmid addiction systems were detected in plasmids encoding ESBLs (mean 1.29, range = 0-4 per recipient strain). pemKI, hok-sok, ccdAB and vagCD were the most frequently represented systems (Table 4). None of the plasmids harbored parDE or relBE and only 5 IncI1 plasmids carried the pndAC system. The plasmids bearing CTX-M-15 had more addiction systems than those bearing other ESBLs (mean of 1.62 vs 0.73, respectively, P < 0.001). pemKI, vagCD and hok-sok were significantly more prevalent in CTX-M-15-carrying plasmids (Table 4). In addition, the mean number of addiction systems was higher in CTX-M-15-carrying plasmids than in CTX-M-14 carrying ones. Indeed, when the type of replicon was considered, the frequency of addiction systems was the highest in IncF plasmids, which were significantly associated to CTX-M-15-carrying plasmids, and IncI1 ones (mean: 1.90 IncF plasmids and 1.8 IncI1 replicons alone was of the lowest frequency of addiction systems and lacked the ccdAB and vagCD systems. The FIA-FIB-FII replicon type showed the highest frequency

---

Table 1 Number of replicons according to ESBL type identified in the E. coli-recipient strains

| ESBL type | N | F | F multiplicon type | Replicon type | H12 | I1 | L/M | A/C | N | ND |
|-----------|---|---|-------------------|---------------|-----|----|-----|-----|---|----|
| All       | 144 | 85 | 49 | 5 | 9 | 18 | 4 | 16 | 5 | 14 | 5 | 4 | 15 |
| TEM       | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| TEM-26    | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| SHV       | 39 | 12 | 0 | 3 | 5 | 3 | 1 | 14 | 0 | 2 | 5 | 2 | 4 |
| SHV-2a    | 9 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SHV-12    | 30 | 9 | 3 | 5 | 3 | 12 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| CTX-M     | 103 | 73* | 49 | 2 | 4 | 15 | 3 | 2 | 5 | 10 | 0 | 2 | 11 |
| CTX-M-14  | 15 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 9 |
| CTX-M-15  | 88 | 72† | 48 | 2 | 4 | 15 | 3 | 2 | 3 | 7† | 0 | 2 | 2 |

ND: not determined.
*: p < 0.05 for CTX-M ESBLs vs. non CTX-M ESBLs.
†: p < 0.05 for CTX-M-15 ESBL vs. other ESBLs.

Table 2 Phylogenetic groups of ESBL-producing E. coli isolates

| Phylogenetic group | Total | CTX-M producers | No CTX-M producers | CTX-M-15 producers |
|--------------------|-------|-----------------|-------------------|-------------------|
| Total number       | 163 (%) | 118             | 45                | 101               |
| A                  | 54 (33.1) | 34              | 20                | 26                |
| B1                 | 24 (14.7) | 12              | 12                | 10                |
| B2                 | 61 (37.4) | 55†             | 6                 | 52 ‡              |
| D                  | 24 (14.7) | 17              | 7                 | 13                |

†: p < 0.0005 for CTX-M B2 producers vs no CTX-M B2 producers.
‡: p < 0.0005 for CTX-M-15 B2 producers vs no CTX-M-15 B2 producers.
of addiction systems (mean, 2.72), followed by multi-replicon combinations comprising the FIA replicons (Table 4). Statistical analysis showed that vagCD is associated with FIA replicons. Moreover, 10 of the 16 (52.5%) CTX-M-15 plasmids carried by ST131 isolates were bearing the vagCD systems. In fact, the vagCD system was significantly associated to the CTX-M15-producing plasmids carried by ST131 isolates ($P < 0.0001$).

Discussion

This study provides molecular-epidemiological data on ESBL-carrying E. coli isolated in the clinical setting of the two university hospitals of Sfax in Tunisia, in the end of the eighties and the 2000s. This study demonstrates a temporal shift in the prevalence of ESBL types (Figure 1). Thus the CTX-M-type ESBLs have clearly been predominant during the last decade, as has been described worldwide [1,2]. The SHV-2 was the first ESBL to be isolated, in 1984 from a Klebsiella pneumoniae isolate in Tunisia [10]. Until the late 1990s, SHV enzymes, especially SHV-12 and SHV-2a, were the most common ESBLs frequently associated with K. pneumoniae involved in nosocomial outbreaks in many Tunisian hospitals including our hospital [10,15,23]. In the 2000s, the prevalence of CTX-M increased steadily especially CTX-M-15 type, whereas that of SHV decreased dramatically. In fact, all the 29 studied E. coli isolates in 2009 were producing CTX-M-15 ESBL, 2 of these were co-producing SHV-12 ESBL. In accordance with previous reports on distribution of ESBL in Enterobacteriaceae, performed in Tunisia and worldwide, we have shown that the CTX-M-15 ESBL was the most prevalent ESBL in our setting [1,2,12-15]. Recent reports indicate that worldwide dissemination of CTX-M-15 is mediated by clonally related E. coli strains, especially a specific clone of phylogroup B2, ST131 [3,4,24]. Accordingly, in the present study, 24/101 (23.7%) of the CTX-M-15-producing strains belonged to clone ST131. E. coli ST131 was previously reported in Tunisia in different hospitals since 2005 [13,14,24,25]. One of the Tunisian studies performed in Sousse from May 2005 to May 2006 identified clone ST131 in 23/31 (74%) of CTX-M-15-producing E. coli and showed that these 23 isolates had the same pulsotype and the same virulence genotype [14]. However, many reports have demonstrated both homogeneity and considerable diversity in PFGE profiles (<65% similarity) and in virulence gene profiles reflecting the dual phenomenon of recent divergence of the clone from a common ancestor together with ongoing transmission of the clone and ongoing evolution of virulence genotype. Similarly, in the present study the PFGE profiles of the ST131 isolates showed a similarity level of 61% (Figure 2). All these ST131 isolates expressed the commonly described virulence genes in ST131 clone including fimH, iha, sat, kpsM, fyuA and iutA, however many of these isolates expressed uncommon genes in this clone including papG allele II (5 isolates),
Table 3 Distribution of virulence genes (%) in ESBL-producing *E. coli* isolates

| Virulence factors | Total N = 163 (%) | CTX-M producers N = 118 | Non CTX-M producers N = 45 | CTX-M-15 producers N = 101 | CTX-M-15 B2 producers N = 52 | B2 non-ST131 N = 37 | B2 ST131 N = 24 | CTX-M-15 B2 ST131 producers N = 23 |
|------------------|------------------|-------------------------|-----------------------------|---------------------------|-----------------------------|-----------------|----------------|-------------------------------|
| **Adhesin**      |                  |                         |                             |                           |                             |                 |                 |                               |
| **papG I**       |                  |                         |                             |                           |                             |                 |                 |                               |
| **papG II**      | 21 (12.8)        | 19 (16.1) *             | 2 (4.4)                     | 19 (18.8) #              | 15 (28.8) †                | 10 (27.2)       | 5 (20.8)        | 5 (21.7)                      |
| **papG III**     | 36 (22.0)        | 30 (25.4)               | 6 (13.3)                    | 30 (29.7) #              | 25 (48.0) †                | 24 (64.8) γ      | 4 (16.6)        | 4 (17.3)                      |
| **papC**         | 35 (21.4)        | 29 (24.5)               | 6 (13.3)                    | 29 (28.7) #              | 25 (48.0) †                | 25 (67.5) γ      | 3 (12.5)        | 3 (13)                        |
| **fimH**         | 138 (84.7)       | 100 (84.7)              | 38 (84.4)                   | 85 (84.2)                | 51 (98.1) †                | 36 (97.3)        | 24 (100)        | 23 (100)                      |
| **afa/draBC**    | 8 (4.9)          | 4 (3.3)                 | 4 (8.8)                     | 4 (3.9)                  | 2 (3.8)                    | 3 (8.1)          | 1 (4.1)         | 1 (4.3)                       |
| **sfa/foc**      | 26 (15.9)        | 20 (16.9)               | 6 (13.3)                    | 20 (19.8) #              | 18 (34.6) †                | 22 (59.4) γ      | -               | -                             |
| **fimA**         | 49 (30.0)        | 45 (38.1) *             | 4 (8.8)                     | 43 (42.5) #              | 36 (69.2) †                | 14 (37.8) γ      | 24 (100)        | 23 (100)                      |
| **hlyA**         | 38 (23.3)        | 29 (24.5)               | 9 (20.0)                    | 28 (27.7)                | 19 (36.5) †                | 24 (64.8) γ      | -               | -                             |
| **Tol plasmid**  | 104 (63.8)       | 78 (66.1)               | 26 (57.7)                   | 68 (67.3)                | 49 (94.2) †                | 33 (89.1)        | 24 (100)        | 23 (100)                      |
| **iutA**         | 82 (50.3)        | 65 (55.0) *             | 17 (37.7)                   | 60 (59.4)                | 37 (71.2) †                | 16 (43.2) γ      | 24 (100)        | 23 (100)                      |
| **Toxin**        | 27 (16.5)        | 24 (20.3) *             | 3 (6.6)                     | 23 (22.8) #              | 22 (42.3) †                | 24 (64.9) γ      | 2 (8.3)         | 2 (8.6)                       |
| **hyA**          | 19 (11.6)        | 17 (14.4)               | 2 (4.4)                     | 17 (16.8) #              | 14 (26.9) †                | 15 (40.5) γ      | -               | -                             |
| **srtA**         | 38 (23.3)        | 37 (31.3) *             | 1 (2.2)                     | 35 (34.6) #              | 30 (57.6) †                | 8 (21.6) γ       | 24 (100)        | 23 (100)                      |
| **Cell protection** | 119 (73.0)       | 94 (79.6) *             | 25 (55.5)                   | 84 (83.2) #              | 40 (76.9) †                | 28 (75.5)        | 18 (75)         | 18 (78.2)                     |
| **traT**         | 69 (42.3)        | 64 (54.2) *             | 5 (11.1)                    | 59 (58.4)                | 45 (86.5) †                | 27 (72.9) γ      | 23 (95.8)        | 22 (95.6)                     |
| **Other pheR**   | 98 (60.1)        | 73 (61.8)               | 25 (55.5)                   | 65 (64.3)                | 35 (67.3)                  | 22 (59.4)        | 17 (70.8)        | 16 (69.5)                     |

*: p < 0.05 for CTX-M producers vs. non CTX-M producers.
†: p < 0.05 for CTX-M-15 producers vs. non CTX-M producers.
‡: p < 0.05 for CTX-M-15 B2 producers vs. other phylogroup isolates with CTX-M-15.
γ: p < 0.05 for B2 non-ST131 isolates vs. B2 ST131 isolates.

papG allele III (4 isolates), papC (3 isolates), afa/draBC (1 isolate) and hlyA (2 isolates) (Table 2). Clermont et al have shown that the phylogroup B2 pandemic clone ST131 is highly virulent in a mouse model, even though it lacks several genes encoding key virulence factors (Pap, CnfI, HylA) [26]. Nevertheless, the recent findings of Johnson et al point away from ST131 isolates as having higher virulence potential compared with other *E. coli* types in causing invasive infections in a murine sepsis model [27]. Moreover, a recent study have demonstrated that the ST131 clone has a genetic composition that differs from other group B2 strains, and appears to be less virulent than previously suspected [28]. In fact, in the present study, the non-ST131-group B2 isolates, which were significantly associated to CTX-M-15 ESBLs, had a higher frequency of several genes encoding key virulence factors such as adhesins hra, sfa/foc, papC and PapG II and the toxins hlyA and cnfI than had the ST131 isolates (p < 0.01) (Table 3). Surprisingly, unlike most previously published studies, where the ESBL-producing *E. coli* isolates lacked the toxins hlyA and cnfI, in our collection the group B2 isolates especially those carrying CTX-M had a high frequency of hlyA (42.6%) and cnfI (24.5%) (Table 2) [22]. PFGE typing showed polygenonality with sporadic cases and small clusters indicating that the rapid increase of CTX-M-15 producing *E. coli* isolates could be due to the incorporation of *bla*<sub>CTX-M-15</sub> genes into group B2 clones exhibiting high number of virulence factors as well as ST131. Although ST131 was predominant in 2003-2004, it appeared to be replaced by group B2 strains exhibiting a higher number of virulence factors in 2006 and 2009. The successful spread of CTX-M-15 was reported to be also related to IncF plasmids. The *bla*<sub>CTX-M-15</sub>-carrying plasmid studied here were also assigned to incompatibility groups IncF in 72/88 plasmids and rarely to IncL/M, IncI, IncN and IncHI2. However, unlike other previous reports, *bla*<sub>CTX-M-14</sub> was carried often on non-typeable plasmids (9/15) and not on Inc K or IncF replicons [5]. More than half of the IncF plasmids carrying *bla*<sub>CTX-M-15</sub> are widely widespread; however, IncF multireplicon plasmids, particularly FII-FIA-FIB, are
increasingly reported to be associated to \textit{bla}_{CTX-M-15}, which can promote stability in bacteria \cite{2,5}. IncF plasmid types are shown to be well-adapted to proliferate in \textit{E. coli}, but their successful retention in \textit{E. coli} populations may also be attributed to the presence of addiction systems. In deed, here the frequency of addiction system was significantly highest in IncF plasmids particularly multireplicon comprising IncFIA. This is consistent with similar studies conducted in France and recently in UK \cite{7,8}. The \textit{pemKI}, \textit{hok-sok}, and \textit{ccdAB} were previously characterized in IncF replicons; however the \textit{vagCD} system which was reported on \textit{Salmonella} virulence plasmids was surprisingly abundant in IncF CTX-M-15 carrying plasmids in the three studies \cite{9,29}. Of note, the \textit{vagCD} system was significantly

\textbf{Table 4 Nature and number of addiction systems according to ESBL type and replicon type identified in the recipient strains}

| Addiction modules, n | ESBL type | n | pemK\textsuperscript{a} | ccdAB | hok-sok\textsuperscript{b} | pndAC | vagCD\textsuperscript{c} | Total | Mean\textsuperscript{d} |
|---------------------|-----------|---|-----------------|-------|------------------|------|-----------------|------|------------------|
| All                 | 144       | 84 | 29              | 51    | 5                | 18   | 187             | 1.29 |
| TEM-26              | 2         | 2  | 0               | 0     | 0                | 0    | 2               |      |
| SHV                 | 39        | 12 | 9               | 7     | 0                | 3    | 31              | 0.79 |
| SHV-2a              | 9         | 1  |                 |       |                  |      | 1               |      |
| SHV-12              | 30        | 11 | 9               | 7     | 0                | 3    | 30              | 1.00 |
| CTX-M               | 103       | 70 | 20              | 44    | 5                | 15   | 154             | 1.46 |
| CTX-M-14            | 15        | 6  | 0               | 0     | 2                | 0    | 8               | 0.53 |
| CTX-M-15            | 88        | 64 | 20              | 44    | 3                | 15   | 143             | 1.62 |
| Replicon type       |           |    |                 |       |                  |      |                 |
| pemK\textsuperscript{e} | IncF vs other plasmids, p < 0.001. |
| ccdAB\textsuperscript{f} | IncF vs other plasmids, p < 0.001. |
| hok-sok\textsuperscript{g} | IncF vs other plasmids, p < 0.001. |
| vagCD\textsuperscript{h} | IncF vs other plasmids, p = 0.08, vagCD: IncF and IncI vs other plasmids, p = 0.01. |
| Mean\textsuperscript{i} | IncF vs other plasmids, p < 0.001. |
| A/C                 | 5         | 0  | 0               | 0     | 0                | 0    | 0               |      |
| N                   | 4         | 0  | 0               | 0     | 0                | 0    | 0               |      |
| L/M                 | 14        | 9  | 0               | 0     | 0                | 0    | 9               | 0.64 |
| IND                 | 15        | 4  | 1               | 0     | 0                | 0    | 5               | 0.33 |
| I1                  | 5         | 2  | 0               | 0     | 5                | 2    | 9               | 1.80 |
| HI2                 | 16        | 0  | 0               | 0     | 0                | 2    | 2               | 0.12 |
| F                   | 85        | 69 | 29              | 50    | 0                | 14   | 162             | 1.90 |
| SHV                 | 12        | 10 | 9               | 6     | 0                | 1    | 26              | 2.16 |
| CTX-M               | 73        | 59 | 20              | 44    | 0                | 13   | 136             | 1.87 |
| FII                 | 49        | 40 | 1               | 32    | 0                | 1    | 74              | 1.51 |
| CTX-M-15            | 48        |     |                 |       |                 | 1    |                 |
| FII-FIB             | 4         | 2  | 1               | 2     | 0                | 0    | 5               | 1.25 |
| SHV-2a              | 1         | 0  | 0               | 0     | 0                | 0    | 0               |      |
| CTX-M-15            | 3         | 2  | 1               | 2     | 0                | 0    |                 |
| FII-FIA-FIB         | 18        | 15 | 14              | 11    | 0                | 9    | 49              | 2.72 |
| SHV-12              | 3         | 3  | 2               | 0     | 0                | 0    | 0               |      |
| CTX-M-15            | 15        | 12 | 12              | 9     | 9                |      |                 |
| FII-FIA             | 9         | 8  | 8               | 3     | 0                | 4    | 23              | 2.55 |
| SHV-12              | 5         | 5  | 4               | 1     | 1                |      |                 |
| CTX-M-15            | 4         | 3  | 4               | 2     | 3                |      |                 |
| FIA-FIB             | 5         | 4  | 5               | 2     | 0                | 0    | 11              | 2.20 |
| SHV-12              | 3         | 2  | 3               | 2     | 2                |      |                 |
| CTX-M15             | 2         | 2  | 2               | 0     | 0                |      |                 |

\footnotesize{\textsuperscript{a} pemK: CTX-M vs SHV, p < 0.001; CTX-M-15 vs other ESBLs, p < 0.001.}

\footnotesize{\textsuperscript{b} hok-sok: CTX-M vs SHV, p < 0.01; CTX-M-15 vs other ESBLs, p < 0.001.}

\footnotesize{\textsuperscript{c} vagCD: CTX-M vs SHV, p = 0.23; CTX-M-15 vs other ESBLs, p = 0.03.}

\footnotesize{\textsuperscript{d} Mean: CTX-M vs SHV, p < 0.001; CTX-M-15 vs other ESBLs, p < 0.001.}

\footnotesize{\textsuperscript{e} pemK: IncF vs other plasmids, p < 0.001.}

\footnotesize{\textsuperscript{f} ccdAB: IncF vs other plasmids, p < 0.001.}

\footnotesize{\textsuperscript{g} hok-sok: IncF vs other plasmids, p < 0.001.}

\footnotesize{\textsuperscript{h} vagCD: IncF vs other plasmids, p = 0.08, vagCD: IncF and IncI vs other plasmids, p = 0.01.}

\footnotesize{\textsuperscript{i} Mean: IncF vs other plasmids, p < 0.001.}
associated to CTX-M-15-plasmids carried on ST131 clone in both the present study and the UK one (10/17 (58.8%) and 26/39 (66%); respectively) [8]. In addition, another recent study conducted in South Korea has shown that vagCD system was more frequently found in CTX-M-15-producing E. coli than in CTX-M-14-producing ones and was surprisingly of high frequency in the main ST11 and ST15 CTX-M-producing K. pneumoniae clones found in South Africa [30]. Moreover, two recent other studies have reported the presence of vagCD in IncA/C plasmids carrying two successful carbapenemases NDM-1 and VIM-1 in South Africa and in Canada, respectively [31,32]. Thus this module, VagCD, appears to play a role in spread and maintenance of many successful plasmids and resistant clones worldwide. Finally, plasmid addiction systems present exciting opportunities for the development of novel antibacterial agents targeting pathogens harboring multi-drug resistance plasmids. In fact, the exploitation of addiction systems as an antibacterial strategy via artificial activation of the toxin has been proposed and has considerable potential; however efforts in this area remain in early stages and many challenges are associated with artificial toxin activation [33].

Conclusion
In conclusion, the present study demonstrates the rapid increase of CTX-M-producing E. coli isolates in Sfax-Tunisia and the decline of SHV-type, mediated mainly with the highly conjugative and adapted IncF plasmids carrying blaCTX-M-15. This study furthermore illustrates that the high prevalence of CTX-M-15 is not only due to the spread of a single clone, mainly the pandemic ST131 clone, but is also associated to the spread of various IncF-type plasmids harboring multiple addiction systems, especially the vagCD system, into related clones with high frequency of virulence determinants. The vagCD system, which is associated to Salmonella virulence plasmids, was significantly associated to the pandemic ST131 clone and has been increasingly reported in various plasmids encoding successful β-lactamases. Based on these findings, larger multicenter studies to determine the contribution of the addiction systems particularly vagCD in the maintenance and spread in of many successful multi-drug resistance plasmids worldwide are warranted. Finally the artificial activation of the VagC, the toxin of the VagCD module, could be an exciting opportunity for the development of novel antibacterial agents targeting many clones bearing successful multi-drug resistance plasmids.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
Conception and design of the study: BM, GA, AH. Laboratory work: BM, HH, NG. Data analysis and interpretation: BM, JJ. Manuscript writing, review, and/or revision: BM, GA, AH. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by the Ministry of Scientific Research Technology and Competence Development of Tunisia and the Pierre et Marie Curie University of France.

Author details
1Laboratoire de Microbiologie, Hôpital Habib Bourguiba, Sfax, Tunisie.
2Service de médecine préventive, Hôpital Hedi Chaker, Sfax, Tunisie.
3Faculté de Médecine, Site Saint-Antoine, Laboratoire de Bactériologie, Université Pierre et Marie Curie-Paris-6, Paris, France.
4Laboratoire de Microbiologie-Faculté de Médecine de Sfax, Avenue Majida Boulla, 3027, Sfax, Tunisie.

Received: 28 March 2013 Accepted: 27 May 2013
Published: 25 June 2013

References
1. Cantón R, Gonzalez-Alba JM, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol 2012, 3:110.
2. Poirel L, Bonnin RA, Nordmann P. Genetic support and diversity of acquired extended-spectrum β-lactamases in Gram-negative rods. Infect Genet Evol 2012, 12:883–893.
3. Nicolas-Chanoine MH, Blanco J, Leffon-Guibout V, Demeny R, Alonso MP, Caniç MM, Park YJ, Lavigne JP, Pitout JD, Johnson JR. Intercontinental emergence of Escherichia coli clone O25:H4-ST131 producing CTX-M-15. J Antimicrob Chemother 2008, 61:279–281.
4. Rogers BA, Siddjbat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multi-resistant, community-associated strain. J Antimicrob Chemother 2011, 66:1–14.
5. Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother 2009, 53:2227–2238.
6. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. Antimicrob Agents Chemother 2009, 53:4472–4482.
7. Mnif B, Vimont S, Boyd A, Bourt E, Picard B, Branger C, Denarzur E, Arlet G. Molecular characterization of addiction systems of plasmids encoding extended-spectrum beta-lactamases in Escherichia coli. J Antimicrob Chemother 2010, 65:1599–1603.
8. Doumith M, Dhanji H, Ellington MJ, Hawkey P, Woodford N. Characterization of plasmids encoding extended-spectrum β-lactamases and their addiction systems circulating among Escherichia coli clinical isolates in the UK. J Antimicrob Chemother 2012, 67:878–885.
9. Gerdes K, Christensen SK, Labner-Olesen A. Prokaryotic toxin-antitoxin stress response loci. Nat Rev Microbiol 2005, 3:371–382.
10. Philippin A, Ben Redjeb S, Ben Hassen A, Djennar E, Ben Arfa G. Characterization and molecular epidemiology of extended-spectrum β-lactamases. Infection 1989, 17:347–354.
11. Hammami A, Arlet G, Ben Redjeb S, Grimont F, Ben Hassen A, Rekkik A, Philippin A. Nosocomial outbreak of acute gastroenteritis in a neonatal intensive care unit in Tunisia caused by multiply drug resistant Salmonella wien producing SHV-2 β-lactamase. J Clin Microbiol Infect Dis 1991, 15:641–646.
12. Mambou K, Boubiba-Ben Boubiba I, Gautier V, Vimont S, Picard B, Ben Redjeb S, Arlet G. Emergence and outbreaks of CTX-M beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae strains in a Tunisian hospital. J Clin Microbiol 2006, 44:4049–4056.
13. Ben Slama K, Ben Sallem R, Jourini A, Rachid S, Moussa L, Saenz Y, Estepa V, Somalo S, Boudabous A, Torres C. Diversity of genetic lineages among CTX-M-15 and CTX-M-14 producing Escherichia coli strains in a Tunisian hospital. Curr Microbiol 2011, 62:1794–1801.
14. Dahmen S, Bettiail D, Mansour W, Boujaafar N, Boudabous A, Arlet G. Characterization and molecular epidemiology of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in a Tunisian University Hospital. Microb Drug Resit 2010, 16:163–170.
15. Elhuni D, Bakir L, Aouni M, Passet V, Arlet G, Brisse S, Weill FX. Molecular epidemiology of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strains in a University Hospital in Tunis, Tunisia, 1999-2005. Clin Microbiol Infect 2010, 16:157–164.
16. CLSI. Performance standards for antimicrobial susceptibility testing. M100-S19. Wayne, PA: CLSI; 2009.
17. Dallenne C, Da Costa A, Decré D, Favier C, Arlet G: Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae. J Antimicrob Chemother 2010, 65:490–495.

18. Clermont O, Bonacorsi S, Bingen E: Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000, 66:4555–4558.

19. Clermont O, Dhanji H, Upton M, Gbreet T, Fox A, Boyd D, Mulvey MR, Nordmann P, Ruppé E, Sarthou JL, Frank T, Vimont S, Arlet G, Branger C, Woodford N, Denamur E: Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. J Antimicrob Chemother 2009, 64:274–277.

20. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B: Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995, 33:2233–2239.

21. Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ: Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 2005, 63:219–228.

22. Karaki E, Ellington MI, Livermore DM, Woodford N: Virulence factors in Escherichia coli with CTX-M15 and other extended-spectrum Beta-lactamases in the UK. J Antimicrob Chemother 2008, 61:54–58.

23. Ben-Hamouda T, Foulon T, Ben-Mahrez K: Involvement of SHV-12 and SHV-2α encoding plasmids in outbreaks of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a Tunisian neonatal ward. Microb Drug Resist 2004, 10:132–138.

24. Lavollay M, Mamlouk K, Frank T, Akpabie A, Burghoffer B, Ben Redjeb S, Bercion R, Gautier V, Arlet G: Clonal dissemination of a CTX-M-15 beta-lactamase-producing Escherichia coli strain in the Paris area, Tunis, and Bangui. Antimicrob Agents Chemother 2006, 50:2433–2438.

25. Jouni A, Ben Slaoui K, Vinaux L, Ruiz E, Samel Y, Sonaro S, Ilii N, Zarzaga M, Ben Moussa M, Boudabous A, Tames C: Detection of unrelated Escherichia coli strains harboring genes of CTX-M-15, OXA-1, and AAC(6′)-Ib-cr enzymes in a Tunisian hospital and characterization of their integrons and virulence factors. J Chemother 2010, 22:318–323.

26. Clermont O, Lavollay M, Vimont S, Deschamps C, Forester C, Branger C, Denamur E, Arlet G: The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J Antimicrob Chemother 2008, 61:1024–1028.

27. Johnson JR, Porter SB, Zhanel G, Kuskowski MA, Denamur E, Arlet G, Tenover FC, Arbeit RD: Virulence of Escherichia coli clinical isolates in a murine sepsis model in relation to sequence type ST131 status, fluoroquinolone resistance, and virulence genotype. Infect Immun 2012, 80:1594–1562.

28. Lavigne JP, Vergunst AC, Goret L, Combes C, Blanco J, O’Callaghan D, Nicolas-Chanoine MH: Virulence potential and genomic mapping of the worldwide clone Escherichia coli ST131. PLoS One 2012, 7:e34294.

29. Pullinger GD, Lax AJ: A Salmonella dublin virulence plasmid locus that affects bacterial growth under nutrient-limited conditions. Mol Microbiol 1992, 6:1631–1643.

30. Shen J, Kim DH, Ko KS: Comparison of CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae isolates from patients with bacteremia. J Antimicrob Chemother 2011, 63:39–47.

31. Peiango G, Pillai DR, Pittorino-Silva A, Richardson D, Pitout JD: The characteristics of NDM-producing Klebsiella pneumoniae from Canada. Diagn Microbiol Infect Dis 2011, 71:106–109.

32. Peiango G, Moorman J, Pittorino-Silva A, Pitout JD: The characteristics of VIM-1-producing Klebsiella pneumoniae from South Africa. Scand J Infect Dis 2012, 44:74–78.

33. Williams JJ, Hergenrother PJ: Artificial activation of toxin-antitoxin systems as an antibacterial strategy. Trends Microbiol 2012, 20:291–298.

Cite this article as: Mnif et al.: Molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli in Tunisia and characterization of their virulence factors and plasmid addiction systems. BMC Microbiology 2013 13:147.